

## Patent body dismisses S Korean firm's appeal on haemophilia drug

Refuses to reverse  
2009 order  
denying patent

### OUR BUREAU

Chennai, June 24

In a setback to South Korean drug-maker Green Cross Holdings, the Indian patent authority has dismissed its appeal for the reversal of a 2009 order by the Deputy Controller of Patents that denied it a patent for its haemophilia drug.

The company's claims that its product to battle blood clot anomalies is novel have

been summarily rejected by the Delhi Bench of the Intellectual Property Appellate Board (IPAB). In their observations, S Usha, Vice-Chairman, IPAB, and DPS Parmar, Technical Member (Patents), have said the experimental discovery does not "constitute a patentable contribution."

### Lacks inventive step

The company had argued that the product does not contain human blood-derived albumin, which can transmit viruses such as the immunodeficiency virus (HIV) or TT virus.

Instead, it used amino

acids such as arginine, isoleucine, and glutamic acid combined in novel ratios to create a stabiliser for the drug.

However, after hearing out the counsel for the company, the Bench declared the product lacks the inventive step, because it does not differ to a great degree from inventions in the past.

Green Cross markets a range of blood coagulants across 50 countries. One such is the prescription drug GreenGene F. The company exports the drug and its variants to the US, CIS nations and a number of countries in Asia including India.

Patent.